IntelGenx’s Anti-Depressant, CPI-300, Receives FDA Approval

IntelGenx is at the forefront of the industry with CPI-300 being the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.

Read more »

VisionCare’s FDA Approved Telescope Gets Implanted

VisionCare’s lead product, Implantable Miniature Telescope by Dr. Isaac Liphitz, enlarges images in front of the eye approximately 2.5 times their normal size.

Read more »

December 10-13, 2011 ASH Annual Meeting and Exposition

December 10-13, 2011 1:00 AM – 1:00 AM San Diego, CA 2011 Annual Meeting abstracts, final program, and personal scheduler […]

Read more »

December 8-9, 2011 FDA/CMS Summit

The Mayflower Renaissance, Washington DC Connect with top policy makers and executives – face-to-face – to develop personalized strategies and […]

Read more »

Editor’s Note November 15, 2011

OneMedForum SF 2012 is around the corner and we are gearing up to present some of the most promising companies […]

Read more »

PLC Medical Systems Uses Revenue in the EU to Fund Phase III Development in the US

Mark Tauscher, President and CEO of PLC Medical Systems Inc., discusses the company’s product RenalGuard, an important tool for ridding the body of toxins.

Read more »

Read more »

Hepregen Corp. Introduces Toxicity Screening Platform

Hepregen is focused on improving and commercializing its microliver platform, HepatoPac, into the drug-development pipeline of pharmaceutical and biotechnology companies.

Read more »

Special Panels Present Significant Opportunity at OneMedForum SF 2012

Panels consisting of leading strategic and financial investors will be followed by short presentations by promising companies. Over 100 companies will present.

Read more »

Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment

DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.

Read more »